DE602005011321D1 - Deamidiertes interferon-beta - Google Patents

Deamidiertes interferon-beta

Info

Publication number
DE602005011321D1
DE602005011321D1 DE602005011321T DE602005011321T DE602005011321D1 DE 602005011321 D1 DE602005011321 D1 DE 602005011321D1 DE 602005011321 T DE602005011321 T DE 602005011321T DE 602005011321 T DE602005011321 T DE 602005011321T DE 602005011321 D1 DE602005011321 D1 DE 602005011321D1
Authority
DE
Germany
Prior art keywords
beta
deamidated
interferon
deamided
interferon beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005011321T
Other languages
German (de)
English (en)
Inventor
Kenji Furuya
Deborah Johnson-Jackson
Diana Tierra Ruscio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE602005011321D1 publication Critical patent/DE602005011321D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602005011321T 2004-11-10 2005-11-10 Deamidiertes interferon-beta Expired - Lifetime DE602005011321D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
PCT/US2005/040758 WO2006053134A2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Publications (1)

Publication Number Publication Date
DE602005011321D1 true DE602005011321D1 (de) 2009-01-08

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011321T Expired - Lifetime DE602005011321D1 (de) 2004-11-10 2005-11-10 Deamidiertes interferon-beta

Country Status (16)

Country Link
US (2) US7595040B2 (enExample)
EP (1) EP1809662B1 (enExample)
JP (1) JP4891250B2 (enExample)
KR (1) KR101330626B1 (enExample)
CN (1) CN101056890B (enExample)
AT (1) ATE415421T1 (enExample)
AU (1) AU2005304486B2 (enExample)
BR (1) BRPI0517697A (enExample)
CA (1) CA2587061C (enExample)
DE (1) DE602005011321D1 (enExample)
ES (1) ES2318575T3 (enExample)
MX (1) MX2007004990A (enExample)
PL (1) PL1809662T3 (enExample)
PT (1) PT1809662E (enExample)
RU (1) RU2404190C2 (enExample)
WO (1) WO2006053134A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
MX2009001348A (es) * 2006-08-08 2009-05-11 Novartis Ag Interferon-beta recombinante con actividad biologica mejorada.
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
CN106132983B (zh) * 2014-04-04 2021-03-26 阿雷斯贸易股份有限公司 新型IFN-β蛋白类似物
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
NZ336548A (en) * 1996-12-24 2001-09-28 Biogen Inc Stable liquid interferon formulations comprising an amino acid as the stabilising agent
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
IL135186A0 (en) * 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
DE60045247D1 (de) 1999-07-28 2010-12-30 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
RU2216345C1 (ru) * 2002-03-21 2003-11-20 Закрытое Акционерное Общество "Биокад" Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием
KR100541850B1 (ko) * 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
EP1809662B1 (en) 2008-11-26
WO2006053134A3 (en) 2006-08-31
ES2318575T3 (es) 2009-05-01
AU2005304486B2 (en) 2011-08-11
KR101330626B1 (ko) 2013-11-18
JP2008519769A (ja) 2008-06-12
US20090263355A1 (en) 2009-10-22
CN101056890B (zh) 2012-05-09
JP4891250B2 (ja) 2012-03-07
RU2007121515A (ru) 2008-12-20
CN101056890A (zh) 2007-10-17
US7595040B2 (en) 2009-09-29
EP1809662A2 (en) 2007-07-25
CA2587061A1 (en) 2006-05-18
CA2587061C (en) 2011-08-16
WO2006053134A2 (en) 2006-05-18
RU2404190C2 (ru) 2010-11-20
AU2005304486A1 (en) 2006-05-18
PT1809662E (pt) 2009-02-26
BRPI0517697A (pt) 2008-10-14
MX2007004990A (es) 2007-06-14
US20060120998A1 (en) 2006-06-08
ATE415421T1 (de) 2008-12-15
PL1809662T3 (pl) 2009-07-31
KR20070084559A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
DE60042122D1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
BRPI0514790A (pt) muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
ATE388963T1 (de) Homogene herstellungen von il-29
NZ754961A (en) Growth differentiation factor 15 (gdf-15) constructs
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
ATE417595T1 (de) Keratin-bindende polypeptide
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
MX2021007434A (es) Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica.
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE415421T1 (de) Deamidiertes interferon-beta
Guo et al. Molecular cloning and characterization of a novel bovine IFN-ε
Ketscher et al. ISG15 uncut: Dissecting enzymatic and non-enzymatic functions of USP18 in vivo
MX2009001348A (es) Interferon-beta recombinante con actividad biologica mejorada.
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
WO2008041014A3 (en) Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
MX2009007248A (es) Peptidos bio-activos cortos para modulacion celular e inmunologica.
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
ATE475099T1 (de) Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor)
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
MX2025013582A (es) Proteina insecticida y uso de la misma
Jiang et al. 893 ANTI-INFLAMMATORY CYTOKINES SUPPRESS THE TLR3-INDUCED ANTIVIRAL ACTIVITY OF NON-PARENCHYMAL LIVER CELLS
de Rueda et al. 891 IMPORTANCE OF HLA-DQB1* 0301 AS PREDICTIVE FACTOR OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITISC (CHC), GENOTYPE-1, TREATED WITH PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition